Three oral formulations of methadone: A clinical and pharmacodynamic comparison

Marc N. Gourevitch, Diana Hartel, Peter Tenore, Katherine Freeman, Ira Marion, Joe Hecht, Joyce Lowinson

Research output: Contribution to journalArticlepeer-review


This study was done to determine whether there were any differences in subjective symptoms of opiate withdrawal or methadone pharmacodynamics among patients as they were switched between three different oral formulations of methadone. Patients enrolled in a three-way double-blind crossover trial of three methadone formulations. Subjective symptoms and pharmacodynamic measures were assessed throughout the study period. Eighteen patients were enrolled the study. No statistically significant differences in any of the pharmacodynamic parameters studied were found among the three methadone preparations. There was no significant difference among preparations in the rate and extent of rise and fall in plasma methadone levels during a 24-hour intensive sampling period. Subjective symptoms also did not correlate with methadone formulation. Intolerance to changes in methadone formulation, often observed clinically, do not appear to have a pharmacodynamic basis. Our findings support the notion that such change intolerance reflects factors other than the pharmacologic properties of the different formulations of methadone.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalJournal of Substance Abuse Treatment
Issue number3
StatePublished - Oct 1999


  • Change intolerance
  • Formulation
  • Methadone
  • Pharmacodynamics
  • Withdrawal

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Three oral formulations of methadone: A clinical and pharmacodynamic comparison'. Together they form a unique fingerprint.

Cite this